Journal of Clinical Epidemiology
Volume 57, Issue 1 , Pages 89-97 , January 2004

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine

  • Amy C Justice

      Affiliations

    • Yale University, New Haven, CT, USA
    • West Haven Veterans Affairs Healthcare System, 950 Campbell Avenue, 11-ACSLG, West Haven, CT 06516, USA
    • Corresponding Author InformationCorresponding author. Tel.: 412-688-6957; fax: 412-688-6916.
    • ,
  • Daniel S Stein

      Affiliations

    • cGlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA
    • ,
  • Gregory P Fusco

      Affiliations

    • cGlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA
    • ,
  • Beth H Sherrill

      Affiliations

    • Research Triangle Institute, P.O. Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    • ,
  • Jennifer S Fusco

      Affiliations

    • cGlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA
    • ,
  • Susan C Danehower

      Affiliations

    • cGlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA
    • ,
  • Stephen L Becker

      Affiliations

    • Pacific Horizon Medical Group, 2351 Clay Street, Suite 412, San Francisco, CA 94115, USA
    • ,
  • Nellie I Hansen

      Affiliations

    • Research Triangle Institute, P.O. Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    • ,
  • Neil M.H Graham

      Affiliations

    • Virco Laboratories Inc., 2505 Meridian Parkway, Suit 350, Durham, NC 27713, USA1
    • ,
  • the CHORUS Program Team

,Accepted 18 February 2003.

References 

  1. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine-induced toxicity. N Engl J Med. 1990;322:1098–1105
  2. Peters BS, Winer J, Landon DN, Stotter A, Pinching AJ. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. QJM. 1993;86:5–15
  3. McLeod GX, Hammer SM. Zidovudine: five years later. Ann Intern Med. 1992;117:487–501
  4. Lutton JD, Mathew A, Levere RD, Abraham NG. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol. 1990;35:1–5
  5. Moore RD, Wong WME, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS. 2000;14(3):273–278
  6. McCarthy WF, Gable J, Lawrence J, Thompson M. A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals. Pharmacoepidemiol Drug Saf. 2000;9(1):49–53
  7. Adkins JC, Peters DH, Faulds D. Zalcitabine: an update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs. 1997;53:1054–1080
  8. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol. 1999;30:156–160
  9. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med. 1994;235:367–371
  10. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. [letter] AIDS. 1997;11:1294–1296
  11. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 1993;7:379–385
  12. Stein DS. A new syndrome of hepatomegaly with severe steatosis in HIV seropositive patients. AIDS Clin Care. 1994;6:17–20 26
  13. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735–1744
  14. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417–422
  15. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′, 3′-dideoxycytidine. J Biol Chem. 1989;264:11934–11937
  16. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother. 1994;38:1824–1828
  17. Chen CH, Vazquez PM, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991;39:625–628
  18. Clumeck N. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy. Antivir Ther. 1998;3(suppl 4):39–43
  19. Katlama C, Valantin M-C, Matheron S, Coutellier A, Calvez V, Descamps D, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naïve and treatment-experienced patients with HIV-1 infection. Ann Intern Med. 1998;129:525–531
  20. Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, et al. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. AIDS. 1999;13:685–694
  21. Foudraine NA, de Jong JJ, Weverling GJ, van Benthem BHB, Maas J, Keet IPM, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS. 1998;12:1513–1519
  22. Martinez E, Perez B, Garcia MA, Blanco JL, Buira E, Mallolas J, Gatell JM. Risk factors for developing lipodystrophy in patients receiving protease inhibitors [Abstract 15]. 7th Conference on Retroviruses and Opportunistic Infections, Jan 30–Feb 2, 2000, San Francisco, USA.
  23. Molina JM, Angelini E, Cotte L, Lang JM, Moriat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G, Chene G and The ALBI Study Group. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors, ALBI Trial (ANRS 070) [Abstract 19]. 7th Conference on Retroviruses and Opportunistic Infections, Jan 30–Feb 2, 2000, San Francisco, USA.
  24. Goujard C, Lascaux AS, Dulioust A, Boue F, Delfraissy JF, Sobel A, Boufassa F, and The LipoSud Study Group. Lipodystrophy in PI-naïve patients treated with RTI combinations: Frequency and risk factors [Abstract 20]. 7th Conference on Retroviruses and Opportunistic Infections, Jan 30–Feb 2, 2000, San Francisco, USA.
  25. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang J-M, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667
  26. Carr A, Miller J, Law M, Cooper D. A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV NRTI therapy: a contribution to PI-related LD syndrome. Antiviral Ther. 1999;4(suppl 2):19–20
  27. Boufassa F, Dulioust A, Goujard C, Lascaux AS, Feneant-Thibault M, and the LipoSud Study Committee. Lipodystrophy and metabolic changes in HIV-infected patients treated with or without PIs [Abstract 48]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 26–28 June 1999, San Diego, USA.
  28. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997;350:1596
  29. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS. 1998;12:F37–F39
  30. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV-1 protease inhibitors. AIDS. 1998;12:F51–F58
  31. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112–1115
  32. Kakuda, TN, Brundage RC, Anderson PL, Fletcher CV. NRTI-induced mitochondrial toxicity as an aetiology for fat redistribution syndrome [Abstract 41]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 26–28 June 1999, San Diego, USA.
  33. Schapira AH. Inborn and induced defects of mitochondria. Arch Neurol. 1998;55:1293–1296
  34. Hirano N, Silvestri D, Blake DM. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology. 1994;44:721–727
  35. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316
  36. Cui L, Locatelli L, Xie MY, Sommadossi JP. Effects of nucleoside analogues on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther. 1997;280(3):1228–1234
  37. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37–49
  38. Mallal S, John M, Moore C, James I, Mckinnon E. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection. Antiviral Ther. 1999;4(suppl 2):28–29
  39. Galli M, Ridolfo AL, Gervasoni C, Ravasio L, Adorni F, Moroni M. Incidence of fat tissue abnormalities in protease inhibitor-naïve patients treated with NRTI combinations. Antiviral Ther. 1999;4(suppl 2):29
  40. Allison PD. Event history analysis: regression for longitudinal event data. In: Quantitative applications in the social sciences. A Sage University Press Paper. Newbury Park, CA: Sage Publications; 1984;
  41. Strom BL, Melmon KL. The use of pharmacoepidemiology to study beneficial drug effects. In:  Strom BL editors. Pharmacoepidemiology. Chapt 23:New York: Churchill Livingstone; 1989;p. 307–324

PII: S0895-4356(03)00245-2

doi: 10.1016/S0895-4356(03)00245-2

Journal of Clinical Epidemiology
Volume 57, Issue 1 , Pages 89-97 , January 2004

Article Tools

* Image Usage & Resolution